Javier Burruchaga
General Pacheco, B, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer.
Journal: British journal of cancer
Published: October 03, 2025
Deciphering the causes of advanced-stage disease at diagnosis among breast cancer patients who attended a suburban hospital in Buenos Aires.
Journal: Medicina
Published: October 14, 2024
Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country.
Journal: Scientific reports
Published: September 10, 2024
FGFR2-RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression.
Journal: International journal of cancer
Published: March 18, 2024
Steroid profile in patients with breast cancer and in mice treated with mifepristone.
Journal: Endocrine-related cancer
Published: July 25, 2023
Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 30, 2022
Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
Journal: International journal of cancer
Published: September 03, 2021
Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer.
Journal: Breast cancer research and treatment
Published: December 09, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026